During the last session, Trevi Therapeutics Inc (NASDAQ:TRVI)’s traded shares were 0.57 million, with the beta value of the company hitting 0.89. At the end
During the last session, Trevi Therapeutics Inc (NASDAQ:TRVI)’s traded shares were 1.34 million, with the beta value of the company hitting 0.87. At the end
During the recent session, Trevi Therapeutics Inc (NASDAQ:TRVI)’s traded shares were 0.7 million, with the beta value of the company hitting 0.87. At the last
Trevi Therapeutics Inc (NASDAQ:TRVI)’s traded shares stood at 0.76 million during the last session, with the company’s beta value hitting 0.94. At the close of
In last trading session, Trevi Therapeutics Inc (NASDAQ:TRVI) saw 1.13 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price
Trevi Therapeutics Inc (NASDAQ:TRVI) has a beta value of 0.94 and has seen 1.59 million shares traded in the recent trading session. The company, currently
During the last session, Trevi Therapeutics Inc (NASDAQ:TRVI)’s traded shares were 63.75 million, with the beta value of the company hitting 0.97. At the end
During the recent session, Trevi Therapeutics Inc (NASDAQ:TRVI)’s traded shares were 40.22 million, with the beta value of the company hitting 0.97. At the last
Trevi Therapeutics Inc (NASDAQ:TRVI)’s traded shares stood at 1.99 million during the last session, with the company’s beta value hitting 0.97. At the close of
In the latest trading session, 0.51 million Trevi Therapeutics Inc (NASDAQ:TRVI) shares changed hands as the company’s beta touched 0.97. With the company’s most recent
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
